Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:16 AM ET 10-Q
Financial Results Outdoor Holding Co POWW ▶ Call

Outdoor Holding Q2 2026 Results: Net Income $2.3M, Up 63.6% YoY

Outdoor Holding Co reported net income attributable to common stock shareholders of $1.5 million for the quarter ended September 30, 2026, compared to $0.7 million in the prior year. Total net revenues increased to $13.7 million for the quarter, driven by growth in continuing operations, while the company continued its common stock repurchase program, acquiring over 3.4 million shares during the six-month period.

Key figure
Net income $2.3M · +63.6% YoY
6:16 AM ET 10-Q
Financial Results Cocrystal Pharma, Inc. COCP

Cocrystal Pharma Q3 2026 Results: Net Loss of $3.44M, Loss Widens

Cocrystal Pharma reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year, driven by increased research and development expenses. The company raised substantial doubt about its ability to continue as a going concern, noting that its $4.9 million in cash and restricted cash is insufficient to fund operations for the next 12 months.

Key figure
Net loss $3.44M
6:16 AM ET 10-Q
Financial Results Odysight.ai Inc. ODYS

Odysight.ai Q3 2026 Results: Net Loss of $4.21M, Loss Narrows

Odysight.ai Inc. reported a total asset decrease to $27.1 million as of September 30, 2026, down from $29.0 million at the end of 2025, primarily driven by a reduction in cash and cash equivalents. The company's accumulated deficit grew to $76.7 million, reflecting ongoing operating losses, while shareholders' equity stood at $23.5 million.

Key figure
Net loss $4.21M
6:16 AM ET 10-Q
Financial Results Golden Star Resource Corp. GLNS

Golden Star Resource Q1 2026 Results: Net Loss of $17.4K, Loss Widens

Golden Star Resource Corp. is an exploration stage company with a working capital deficit of $965,666 and no revenue as of September 30, 2026. The company reported a net loss of $17,368 for the quarter, primarily driven by professional and office expenses, raising substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $17.4K
6:16 AM ET Form 4
Insider Buying electroCore, Inc. ECOR

electroCore Insider Thomas J. Errico Buys $54.4K of Stock

Thomas J. Errico bought 10,000 shares of electroCore, Inc. at $5.44 a share, worth $54.4K in total on Nov 12, 2026. Shares held after the trade: 373,904 (+2.7%).

Value
$54.4K
Shares
10,000
Price
$5.44
Holding change
+2.7%
Trade date
Nov 12, 2026
6:16 AM ET Form 4
Insider Buying Amdocs Ltd DOX

Amdocs Director Eliahu Meir Gelman Buys $104K of Stock

Eliahu Meir Gelman, Director, bought 2,500 shares of Amdocs Ltd at $41.72 a share, worth $104K in total on Nov 9, 2026. Shares held after the trade: 353,446 (+0.7%).

Value
$104K
Shares
2,500
Price
$41.72
Role
Director
Holding change
+0.7%
Trade date
Nov 9, 2026
6:15 AM ET Form 4
Insider Buying Yum China Holdings, Inc. YUMC

Yum China Holdings Insider Alexander Dimitrief Buys $248K of Stock

Alexander Dimitrief bought 5,000 shares of Yum China Holdings, Inc. at $49.50 a share, worth $248K in total on Nov 13, 2026. Shares held after the trade: 8,691 (+135.5%).

Value
$248K
Shares
5,000
Price
$49.50
Holding change
+135.5%
Trade date
Nov 13, 2026
6:15 AM ET Form 4
Insider Buying Studio City International Holdings Ltd MSC

Studio City International Holdings Director Lawrence Yau Lung Ho Buys $30.9K of Stock

Lawrence Yau Lung Ho, Director, bought 111,832 shares of Studio City International Holdings Ltd at $0.2631 to $0.2868 a share (average $0.2763) in 2 transactions, worth $30.9K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 463,575,984 (+0.0%).

Value
$30.9K
Shares
111,832
Average price
$0.2763
Role
Director
Holding change
+0.0%
Trade date
Nov 12, 2026 to Nov 13, 2026
6:15 AM ET 8-K
Financial Results Quality Industrial Corp. QIND

Quality Industrial Financial Results

Quality Industrial Corp. reported its Q3 2026 financial results, showing a 3.6% revenue increase to $3.64 million and a return to operating income of $39,978. The company's net loss narrowed significantly to $31,512, driven by a 29.8% reduction in operating expenses and higher sales volumes in its UAE-based LPG distribution subsidiary, Al Shola Gas.

Term
Q3 2026
6:15 AM ET 8-K
Other 8-K Filing Oz Vision Inc. OZVN

Oz Vision Other 8-K Filing

OZ Vision Inc. announced that its audited financial statements for the fiscal years ended June 30, 2025, and June 30, 2026, should no longer be relied upon due to material misstatements regarding intangible assets. The company discovered that a $12.57 million Nevada State Athletic Commission license it had recorded was never validly transferred to the company and was non-transferable. The restatement is expected to eliminate approximately $13.1 million in assets, resulting in a total stockholders' deficit as of June 30, 2026.

Counterparty
Boladale Lawal & CO
6:14 AM ET 8-K
Loan & Debt Lithium Americas Corp. LAC

Lithium Americas $2.26B Debt Financing with United States Department of Energy

Lithium Americas entered into an omnibus amendment with the U.S. Department of Energy (DOE) regarding its $2.26 billion loan facility for the Thacker Pass project. The amendment updates the construction budget, project schedule, and equity funding requirements, including a commitment for $650 million in incremental contributions from the company's existing cash.

Value
$2.26B
Counterparty
United States Department of Energy
6:14 AM ET 8-K
Leadership Change Oscar Health, Inc. OSCR

Oscar Health Leadership Change

Oscar Health appointed Tomer Cohen, Eric Larsen, and Rajat Taneja to its Board of Directors, effective November 13, 2026, increasing the board size from eight to eleven. The new directors bring expertise from LinkedIn, Visa, and healthcare advisory roles, with specific appointments to the Audit, Compensation, and Nominating committees. All three appointees were determined to be independent under NYSE rules.

6:14 AM ET 8-K
Stock Buyback Zymeworks Inc. ZYME

Zymeworks Announces $200M Stock Buyback

Zymeworks authorized a new $200 million share repurchase program through 2028, following the completion of its initial $125 million program. The company expects to spend approximately $140 million under this new authorization to reduce share count and return capital to shareholders.

Value
$200M
Term
through 2028
6:14 AM ET 8-K
Other 8-K Filing Summit Therapeutics Inc. SMMT

Summit Therapeutics Other 8-K Filing

Summit Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for certain lung cancer patients. The FDA determined that the BLA cannot be approved in its current form because the progression-free survival benefit did not establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.

Counterparty
FDA
6:14 AM ET 8-K
Product Launch Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Product Launch

Artificial Intelligence Technology Solutions' subsidiary, Robotic Assistance Devices (RAD), has launched a new Glass Break Detection AI analytic for its ROAMEO autonomous security patrol vehicle. The feature, developed over 17 months, allows the mobile robot to detect the sound of breaking glass and initiate automated investigation and evidence capture. This marks the fifth release of 15 engineering initiatives committed to by the company in July 2026.

6:14 AM ET 8-K
Shareholder Meeting Income Opportunity Realty Investors Inc IOR

Income Opportunity Realty Investors Shareholder Meeting

Income Opportunity Realty Investors held its Annual Meeting of Stockholders on November 11, 2026, where shareholders elected four directors to the board and ratified the appointment of Farmer, Fuqua & Huff, P.C. as the independent auditor for fiscal year 2026. Following the meeting, the board re-elected Henry A. Butler as Chairman and re-appointed Ted Munselle as Presiding Director.

6:14 AM ET 8-K
Financial Results AtlasClear Holdings, Inc. ATCH

AtlasClear Holdings Financial Results

AtlasClear Holdings, Inc. reported financial results for the fiscal quarter and nine months ended September 30, 2026, including the condensed consolidated financial statements of Autonomous Power Corporation. The company reported total revenues of $9.14 million and a net loss of $32.83 million for the nine-month period ended September 30, 2026.

Term
9 months
6:14 AM ET 8-K
M&A Deal Powerus Corp PUSA

Powerus M&A Deal with Autonomous Power Corporation

Powerus Corporation filed historical and pro forma financial statements related to its completed merger with Autonomous Power Corporation (Legacy Powerus). The merger, which closed on October 1, 2026, resulted in Legacy Powerus becoming a direct subsidiary of the company.

Counterparty
Autonomous Power Corporation
6:14 AM ET 8-K
Clinical Trial Data Aclaris Therapeutics, Inc. ACRS

Aclaris Therapeutics Clinical Trial Data

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. Despite robust target engagement and biomarker downregulation, the company will shift focus toward its oral ITK inhibitors and bispecific antibody ATI-052. The company also announced the initiation of a Phase 2b trial for modzatinib in lichen planus and plans to file an IND for ATI-9494 in Q4 2026.

6:14 AM ET 8-K
Capital Raise Vir Biotechnology, Inc. VIR

Vir Biotechnology Capital Raise of $150M

Vir Biotechnology entered into an underwriting agreement to sell 15,000,000 shares of common stock at a public offering price of $10.00 per share. The company expects to receive approximately $140.4 million in net proceeds, or $161.5 million if the underwriters exercise their 30-day option to purchase an additional 2,250,000 shares.

Value
$150M
Counterparty
Leerink Partners LLC
6:14 AM ET 8-K
Investor Meeting Henry Schein Inc HSIC

Henry Schein Investor Meeting

Henry Schein announced a voluntary change to its non-GAAP financial reporting to exclude acquisition-related remeasurement gains starting in Q4 2026. Consequently, the company updated its FY2026 non-GAAP diluted EPS guidance to $5.42-$5.48 from $5.50-$5.56 to reflect this accounting adjustment, with no change to its underlying business outlook.

6:14 AM ET 8-K
Financial Results 22nd Century Group, Inc. XXII

22nd Century Group Financial Results

22nd Century Group reported third quarter 2026 revenue of $4.8 million, a 66% sequential increase, and achieved positive gross profit of $0.4 million. The company highlighted significant retail expansion for its Pinnacle VLN and Pinnacle Pure cigarette products, including a new distribution partnership with Gopuff. Management also noted a simplified capital structure following the redemption of Series B preferred stock and the elimination of outstanding warrants.

Term
Q3 2026

“The third quarter marked a period of accelerating commercial execution featuring expanded market adoption of our Pinnacle branded products. We grew revenue 66% sequentially to $4.8 million, turned gross profit positive, and meaningfully reduced our operating loss, all while continuing to expand retail distribution, increase consumer awareness and strengthen the commercial foundation for our VLN® products.”

Larry Firestone, Chief Executive Officer of 22nd Century Group

“Alongside this commercial progress, we significantly cleaned up our capital structure. Following quarter-end, we raised $5.8 million of net cash proceeds through an at-the-market offering, used $1.2 million of those proceeds to redeem an equal amount of our Series B convertible preferred stock at par, and enter the fourth quarter with no warrants outstanding.”

Larry Firestone, Chief Executive Officer of 22nd Century Group
6:14 AM ET 8-K
Capital Raise Rezolute, Inc. RZLT

Rezolute Capital Raise of $100M

Rezolute, Inc. entered into an underwriting agreement for a public offering of 22,040,976 shares of common stock and 3,800,000 pre-funded warrants, expected to raise gross proceeds of approximately $100 million. The financing was led by Frazier Life Sciences and is intended to fund commercialization preparation for ersodetug and general corporate purposes.

Value
$100M
Counterparty
Frazier Life Sciences
6:14 AM ET 8-K
Investor Presentation Biohaven Ltd. BHVN

Biohaven Investor Presentation

Biohaven Ltd. is delivering an investor presentation at the Jefferies Global Healthcare Conference in London from November 16-19, 2026. The presentation provides a corporate update on the company's clinical pipeline, including programs in glutamate modulation, immunology, and oncology.

6:14 AM ET 8-K
Financial Results Silexion Therapeutics Corp SLXN

Silexion Therapeutics Financial Results

Silexion Therapeutics reported Q3 2026 financial results, highlighting the dosing of the first patient in its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. The company strengthened its balance sheet through a public offering and warrant inducement, ending the quarter with $4.8 million in cash and $3.0 million in shareholders' equity.

Term
Q3 2026

“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”

Ilan Hadar, Chairman and Chief Executive Officer

“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”

Mirit Horenshtein Hadar, Chief Financial Officer
6:14 AM ET 8-K
Nasdaq/NYSE Compliance Notice Kala BIO, Inc. KALA

Kala BIO Nasdaq/NYSE Compliance Notice

KALA BIO received a determination from the Nasdaq Hearings Panel granting its request to continue its listing on The Nasdaq Capital Market subject to specific conditions. The company must evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026, and maintain that price through February 23, 2027. Failure to meet these conditions or any other listing rules during this period may result in delisting.

Counterparty
The Nasdaq Stock Market LLC
Term
through Feb 2027
6:14 AM ET 8-K
Capital Raise DataMeds AI, Inc. MEDS

DataMeds AI Capital Raise

DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.

Counterparty
Dawson James Securities, Inc.
6:12 AM ET 8-K
Dividend T. Rowe Price OHA Select Private Credit Fund OCREDIT

T. Rowe Price OHA Select Private Credit Fund Dividend

T. Rowe Price OHA Select Private Credit Fund declared total distributions of $0.60 per share for the third quarter of 2026, representing an annualized distribution rate of 9.2%. The fund reported net investment income of $0.60 per share and a net asset value (NAV) of $26.02 per share as of September 30, 2026.

Term
Q3 2026
6:12 AM ET 10-Q
Financial Results OHA Senior Private Lending Fund (U) LLC

OHA Senior Private Lending Fund Q3 2026 Results: Net Income $3.24M, Up 30.1% YoY

For the nine months ended September 30, 2026, OHA Senior Private Lending Fund reported a significant decrease in net increase in net assets resulting from operations to $0.29 million, down from $73.96 million in the prior year period, primarily driven by a $26.02 million net unrealized depreciation. Total investment income also saw a decline to $31.00 million compared to $34.62 million in 2025.

Key figure
Net income $3.24M · +30.1% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.